CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
Synthetic Tumor-Specific Breakpoint Peptide Vaccinebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00267085
NCT00267085Phase 2Completed
CompareCT.gov

A Pilot Phase II Trial of a Synthetic Tumor-Specific Breakpoint Peptide Vaccine in Patients With Chronic Myeloid Leukemia (CML) and Minimal Residual Disease

M.D. Anderson Cancer Center·interventional·Posted Dec 20, 2005·Updated Aug 7, 2012

In Brief

A Phase 2 clinical trial evaluating Synthetic Tumor-Specific Breakpoint Peptide Vaccine for Chronic Myeloid Leukemia and Minimal Residual Disease. Completed, enrolled 11 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if giving 1 of 2 CML (Chronic Myeloid Leukemia) vaccines (CML-VAX B2 or CML-VAX B3) together with imatinib mesylate can decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Myeloid Leukemia, Minimal Residual Disease
CountriesUnited States
CollaboratorsBreakThrough Therapeutics

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 20, 2005
Enrollment StartDec 1, 2005
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 20.5 years ago

Interventions

Synthetic Tumor-Specific Breakpoint Peptide Vaccinebiological

CML vaccine, Imatinib mesylate, subcutaneously every 2 weeks x 4 weeks, then every three weeks x 1 week, then monthly for 10 months